~~<i id='8ADD317A52'><strike id='8ADD317A52'><tt id='8ADD317A52'><pre id='8ADD317A52'></pre></tt></strike></i>~~

Home» Wikipedia» knowledge

knowledge

author：focus 2025-09-29 12:54:33 Page View：78325

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： MultiPlan and major insurers sued for alleged medical price
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

focus

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Coloradans with cystic fibrosis could lose access to Trikafta

Illustration:STAT;Source:BusinessWire/APIwaslivingontheprecipiceofend-stagediseasewhenIenrolledinthe

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Brain injuries and the importance of a second opinion

Photoillustration:CaseySheneryforSTATHowoldisClaireSnyman?“Iamnow…”shesayswithpause.“Ialwayshavetoth